National Comorbidity Survey - Adolescent (NCS-A)

全国合并症调查 - 青少年 (NCS-A)

基本信息

项目摘要

During the past year, the major methodological and basic descriptive data have been summarized and submitted for publication. The methodological papers described the NCS-A background and measures (Merikangas et al 2009), study design and sampling (Kessler et al, 2009), field procedures (Kessler et al, 2009) and concordance of DSM-IV diagnosis from CIDI interview with clinical reassessments (Kessler et al, 2009). In addition, substantial work by our Harvard collaborators on the validity of individual diagnostic entities in the NCS-A diagnostic interview has been completed, and several manuscripts describing this work are in various stages of publication (Green et al, a, b, c) The primary effort of the NIMH team during the past year has been to review the diagnostic algorithms that were initially developed at Harvard University in order to , to define severity of cases using higher thresholds for impairment, to develop definitions of subthreshold disorders, and to create variables for service utilization. We have also processed the diagnostic data, developed codebooks and began constructing secondary variables for analysis. The NIMH team has also made substantial progress on defining the priorities for descriptive analyses of several specific disorders including mood, anxiety, eating, migraine, and substance abuse. Work groups including both intramural and extramural collaborators have been established in each of these areas. These efforts have yielded several manuscripts covering a wide range of adolescent mental health topics, including: (1) the prevalence of mental disorders in the U.S. adolescent population, (2) service patterns for mental disorders among these youth, and (3) comprehensive, disorder and topic-specific papers that examine mania, major depression, anxiety, and eating disorders, as well as migraine, suicide, tobacco use, and child neglect. The first publication of lifetime prevalence rates the full range of DSM-IV mental disorders in U.S. adolescents and their individual and familial correlates is now in press. The overall prevalence of disorders with severe impairment and/or distress was 22.2%; (11.2% with mood disorders; 8.3% with anxiety disorders; 9.6% behavior disorders). The median age of onset for disorder classes was earliest for anxiety (6 years), followed by 11 years for behavior, 13 years for mood, and 15 years for substance use disorders. We have also completed the analyses of lifetime service patterns for mental disorders in U.S. adolescents in collaboration with Mark Olfson, Ph.D. of Columbia University. Service rates were highest among those with attention-deficit/hyperactivity disorder (68.0%) and behavior disorders (45.4%), but less than one in five affected adolescents received services for their anxiety, eating or substance use disorders. Hispanic and non-Hispanic black adolescents were less likely than their white counterparts to receive services for mood and anxiety disorders, even when such disorders were associated with severe impairment. The manuscript has been submitted for publication. We have recently completed a parallel analysis for patterns of 12-month service utilization. 45% youth with 12 month disorders received services from any source and are in the process of preparing a manuscript reporting these findings in collaboration with our extramural collaborators. Other analyses that have been conducted and submitted for publication include: (1) A latent class analysis (LCA) on a subsample 2,539 adolescents with lifetime anxiety disorders to identify empirical subgroups and to examine their developmental and clinical correlates. A seven class solution provided the best fit among both males and females, with classes defined primarily by the nature rather than the degree of anxiety. The presentation of anxiety disorders among individuals and the observation of unique correlates of classes provide evidence for the utility of individual DSM-IV anxiety disorder categories. Findings emphasize the potential value of early interventions and gender-specific conceptualization and treatment of anxiety disorders. (2) We have also assessed the prevalence and correlates of eating disorders in the NCS-A. We found that the lifetime prevalence of anorexia nervosa, bulimia nervosa, and binge eating disorder were respectively 0.3%, 0.9%, and 1.6%. Important differences were observed between anorexia nervosa and other eating disorders concerning sociodemographic correlates, psychiatric comorbidity and suicidality. Although the majority of adolescents with an eating disorder sought some form of treatment, only a minority received treatment specifically for their eating or weight problems. Their severity is demonstrated by generally strong associations with other psychiatric disorders, role impairment, and suicidality, and the unmet treatment needs in the adolescent population place these disorders as important public health concerns. (3) We have examined the 12 month prevalence and comorbidity with other physical conditions in the NCS-A. Migraine status in the past 12 months was assessed using modified International Headache Society (HIS) criteria. Presence of other physical conditions was assessed using a questionnaire addressed to a parent or parent surrogate and reported across the spectrum of headache sufferers. We found that the prevalence of migraine without aura was 8.0% (4.9% in males and 11.3% in females) and migraine with aura was 0.9% (0.8% in males and 0.9% in females). Individuals with any type of headache more frequently reported other neurologic conditions such as epilepsy, persistent nightmares, and motion sickness. Adolescents with migraine were more likely to have a diagnosis of asthma and seasonal allergies compared to those with non-specific headache. Two manuscripts have been drafted and have been submitted for publication. During the next year, we plan to: (1) expand our understanding of mental disorders and service utilization in adolescents by examining risk and protective factors at the level of the individual, family, and community; (2 )investigate the role of immigration and school/neighborhood factors on mental disorders in youth; (3) examine patterns of comorbidity between mental and physical disorders; (4) conduct analyses among subgroups linking data from other national and international studies; and (5) complete the salivary stress hormone assays and evaluate their association with mental disorders in adolescents. Public Health Impact: Aside from providing the first prevalence data on a wide range of psychiatric disorders in a nationally representative sample of U.S. adolescents, the results of this study demonstrate that common mental disorders in adults first emerge in childhood and adolescence. The severity of disorders under study is also demonstrated by the high degree of comorbidity, clinical distress, role impairment, and suicidality among youth with mental disorders. In consideration of the substantial proportion of young people with severe mental disorders that have never received specialty mental health care, the marked racial disparities in lifetime mental health treatment for mood and anxiety disorders, the magnitude unmet needs in mental health treatment are of great importance in public health. Our results further highlight the need for a transition from the common focus on treatment of U.S. youth to that of prevention and early intervention. Future work on this rich resource will help to address the dramatic personal and societal impact of adolescent mental disorders in order to help establish sound public health policy and design health programs and services.
在过去的一年里,主要的方法和基本的描述性数据已经总结并提交出版。方法学论文描述了NCS-A的背景和措施(Merikangas et al . 2009)、研究设计和抽样(Kessler et al . 2009)、现场程序(Kessler et al . 2009)以及从CIDI访谈中得出的DSM-IV诊断与临床再评估的一致性(Kessler et al . 2009)。此外,我们的哈佛合作者在NCS-A诊断访谈中个别诊断实体的有效性方面的大量工作已经完成,描述这项工作的几份手稿正处于不同的出版阶段(Green等人,a, b, c)。NIMH团队在过去一年中主要的努力是审查最初在哈佛大学开发的诊断算法,以便:使用更高的损伤阈值来定义病例的严重程度,制定亚阈值障碍的定义,并为服务利用创建变量。我们还处理了诊断数据,开发了代码本,并开始构建用于分析的次要变量。NIMH团队还在确定几种特定疾病的描述性分析优先级方面取得了实质性进展,这些疾病包括情绪、焦虑、饮食、偏头痛和药物滥用。在这些领域都设立了包括内部和外部合作者在内的工作组。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

kathleen r merikangas其他文献

kathleen r merikangas的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('kathleen r merikangas', 18)}}的其他基金

Family Study of African Americans
非裔美国人的家庭研究
  • 批准号:
    6982838
  • 财政年份:
  • 资助金额:
    $ 34.22万
  • 项目类别:
Vulnerability Factors Among Migrant Puerto Rican Fami
波多黎各移民家庭的脆弱因素
  • 批准号:
    6982809
  • 财政年份:
  • 资助金额:
    $ 34.22万
  • 项目类别:
Family Study of Affective and Anxiety Spectrum Disorders
情感和焦虑谱系障碍的家庭研究
  • 批准号:
    8556939
  • 财政年份:
  • 资助金额:
    $ 34.22万
  • 项目类别:
National Health And Nutrition Examination Survey (NHANES)
全国健康与营养检查调查 (NHANES)
  • 批准号:
    8939988
  • 财政年份:
  • 资助金额:
    $ 34.22万
  • 项目类别:
Family Study of Comorbidity of Anxiety Disorders and Sub
焦虑症及其亚型合并症的家庭研究
  • 批准号:
    7312922
  • 财政年份:
  • 资助金额:
    $ 34.22万
  • 项目类别:
Population-Based Epidemiologic Research
基于人群的流行病学研究
  • 批准号:
    10011376
  • 财政年份:
  • 资助金额:
    $ 34.22万
  • 项目类别:
Family Study of African Americans & Vuln. Factors Among Migrant Puerto Ricans
非裔美国人的家庭研究
  • 批准号:
    7594578
  • 财政年份:
  • 资助金额:
    $ 34.22万
  • 项目类别:
Motor Activity Research Consortium for Health (mMarch)
运动健康研究联盟 (mMarch)
  • 批准号:
    10703947
  • 财政年份:
  • 资助金额:
    $ 34.22万
  • 项目类别:
Motor Activity Research Consortium for Health (mMarch)
运动健康研究联盟 (mMarch)
  • 批准号:
    10929839
  • 财政年份:
  • 资助金额:
    $ 34.22万
  • 项目类别:
Family Study of Affective and Anxiety Spectrum Disorders
情感和焦虑谱系障碍的家庭研究
  • 批准号:
    10929813
  • 财政年份:
  • 资助金额:
    $ 34.22万
  • 项目类别:

相似海外基金

睡眠時無呼吸症と睡眠時ブラキシズムのcomorbidityを成立させる病態生理機構の解明
阐明睡眠呼吸暂停和睡眠磨牙症并存的病理生理机制
  • 批准号:
    24K02631
  • 财政年份:
    2024
  • 资助金额:
    $ 34.22万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
ARISTOTELES - Applying ARtificial Intelligence to Define clinical trajectorieS for personalized predicTiOn and early deTEctiOn of comorbidiTy and muLtimorbidiTy pattErnS
亚里士多德 - 应用人工智能定义临床轨迹,以实现个性化预测以及合并症和多发病模式的早期检测
  • 批准号:
    10103153
  • 财政年份:
    2023
  • 资助金额:
    $ 34.22万
  • 项目类别:
    EU-Funded
Macrophage metabolism in diabetes and tuberculosis comorbidity
糖尿病和结核病合并症中的巨噬细胞代谢
  • 批准号:
    10645801
  • 财政年份:
    2023
  • 资助金额:
    $ 34.22万
  • 项目类别:
Resolving sources of heterogeneity and comorbidity in alcohol use disorder
解决酒精使用障碍的异质性和合并症的来源
  • 批准号:
    10783325
  • 财政年份:
    2023
  • 资助金额:
    $ 34.22万
  • 项目类别:
Involvement of dopamine signaling in chronic pain-induced negative affective state and nicotine use comorbidity
多巴胺信号传导参与慢性疼痛引起的负面情感状态和尼古丁使用合并症
  • 批准号:
    10662951
  • 财政年份:
    2023
  • 资助金额:
    $ 34.22万
  • 项目类别:
HIV-1 and Alzheimer’s disease: Comorbidity
HIV-1 和阿尔茨海默病:合并症
  • 批准号:
    10760712
  • 财政年份:
    2023
  • 资助金额:
    $ 34.22万
  • 项目类别:
Insulin-like Growth Factor-1 (IGF-1) signalling in immunometabolism of TB and TB-Diabetes comorbidity
胰岛素样生长因子-1 (IGF-1) 信号在结核病和结核病-糖尿病合并症免疫代谢中的作用
  • 批准号:
    10734113
  • 财政年份:
    2023
  • 资助金额:
    $ 34.22万
  • 项目类别:
Genetic Comorbidity of PTSD and Substance Use Disorders in Diverse Populations.
不同人群中 PTSD 和药物使用障碍的遗传共病。
  • 批准号:
    10658078
  • 财政年份:
    2023
  • 资助金额:
    $ 34.22万
  • 项目类别:
Closing the Comorbidity Gap for People Living with HIV : a Randomized Controlled Trial of Fostemsavir to Reduce Inflammaging
缩小艾滋病毒感染者的合并症差距:Fostemsavir 减少炎症的随机对照试验
  • 批准号:
    485532
  • 财政年份:
    2023
  • 资助金额:
    $ 34.22万
  • 项目类别:
    Operating Grants
New insights into the development of metabolic dysfunction as a comorbidity in Crohn's disease.
关于代谢功能障碍作为克罗恩病合并症的发展的新见解。
  • 批准号:
    493720
  • 财政年份:
    2023
  • 资助金额:
    $ 34.22万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了